Decision Aid–Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Qualitative Study
Authors' conclusion
A DA-led strategy for tapering advanced therapy in RA was acceptable to patients and feasible in practice. Sending patients a DA ahead of their appointment facilitated patient-led conversations about tapering.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in sustained remission tapering biologic disease-modifying antirheumatic drugs (bDMARDs) or tsDMARDs, and rheumatologists, within a pilot study of decision aid (DA)-led tapering
- Participants
- 10 vs 12
- Comparison
- Patients vs Rheumatologists
- Patientsn = 10
- Rheumatologistsn = 12
- Outcome
- Experiences and perspectives on DA-led tapering
Methodological detailssemistructured interviews, reflexive thematic analysis, embedded within a pilot study
- Semistructured interviews
- Reflexive thematic analysis
- Embedded within a pilot study
Main finding
As reported in the abstract
Participating rheumatologists who adopted sending the DA to all eligible patients ahead of appointments, facilitating patient-led conversations
3 of 4
Original publication
Decision Aid–Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Qualitative Study. J Rheumatol. Published 15 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →